Microglial dysfunction is a key pathological feature of Alzheimer's disease (AD), but little is known about proteome-wide changes in microglia during the course of AD and their functional consequences. Here, we performed an in-depth and time-resolved proteomic characterization of microglia in two mouse models of amyloid beta (A beta) pathology, the overexpression APPPS1 and the knock-in APP-NL-G-F (APP-KI) model. We identified a large panel of Microglial A beta Response Proteins (MARPs) that reflect heterogeneity of microglial alterations during early, middle and advanced stages of A beta deposition and occur earlier in the APPPS1 mice. Strikingly, the kinetic differences in proteomic profiles correlated with the presence of fibrillar A bet...
Every 3 seconds someone in the world is diagnosed with dementia. This staggering fact is compounded ...
Abstract Background Alzheimer’s disease (AD), the most common neurodegenerative disorder, is charact...
Microglia activation is the brain's major immune response to amyloid plaques in Alzheimer's disease ...
Microglial dysfunction is a key pathological feature of Alzheimer's disease (AD), but little is know...
Aging is the key risk factor for Alzheimer's disease (AD). In addition, the amyloid-beta (A beta) pe...
Microglial cells closely interact with senile plaques in Alzheimer’s disease and acquire the morphol...
Background Alzheimers disease (AD), the most common neurodegenerative disorder, is ...
Microglia are the primary central nervous system (CNS) immune cell and carry out a variety of import...
Prior work suggests that amyloid precursor protein (APP) can function as a proinflammatory receptor ...
BackgroundGenetic mutations underlying familial Alzheimer's disease (AD) were identified decades ago...
Abstract Background Microglia are innate immune cells of the brain that perform phagocytic and infla...
Abstract Background The accumulation of amyloid beta (Aβ) peptides in fibrils is prerequisite for Al...
The role of microglia cells in Alzheimer's disease (AD) is well recognized, however their molecular ...
BACKGROUND: Genetic mutations underlying familial Alzheimer\u27s disease (AD) were identified decade...
Alzheimer´s disease (AD) is the most common type of dementia representing an estimated 60-80% of all...
Every 3 seconds someone in the world is diagnosed with dementia. This staggering fact is compounded ...
Abstract Background Alzheimer’s disease (AD), the most common neurodegenerative disorder, is charact...
Microglia activation is the brain's major immune response to amyloid plaques in Alzheimer's disease ...
Microglial dysfunction is a key pathological feature of Alzheimer's disease (AD), but little is know...
Aging is the key risk factor for Alzheimer's disease (AD). In addition, the amyloid-beta (A beta) pe...
Microglial cells closely interact with senile plaques in Alzheimer’s disease and acquire the morphol...
Background Alzheimers disease (AD), the most common neurodegenerative disorder, is ...
Microglia are the primary central nervous system (CNS) immune cell and carry out a variety of import...
Prior work suggests that amyloid precursor protein (APP) can function as a proinflammatory receptor ...
BackgroundGenetic mutations underlying familial Alzheimer's disease (AD) were identified decades ago...
Abstract Background Microglia are innate immune cells of the brain that perform phagocytic and infla...
Abstract Background The accumulation of amyloid beta (Aβ) peptides in fibrils is prerequisite for Al...
The role of microglia cells in Alzheimer's disease (AD) is well recognized, however their molecular ...
BACKGROUND: Genetic mutations underlying familial Alzheimer\u27s disease (AD) were identified decade...
Alzheimer´s disease (AD) is the most common type of dementia representing an estimated 60-80% of all...
Every 3 seconds someone in the world is diagnosed with dementia. This staggering fact is compounded ...
Abstract Background Alzheimer’s disease (AD), the most common neurodegenerative disorder, is charact...
Microglia activation is the brain's major immune response to amyloid plaques in Alzheimer's disease ...